Schwab Charles Investment Management Inc. Has $5.07 Million Stake in Intrexon Corporation (XON)
Schwab Charles Investment Management Inc. trimmed its stake in shares of Intrexon Corporation (NYSE:XON) by 7.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 210,450 shares of the biotechnology company’s stock after selling 16,531 shares during the quarter. Schwab Charles Investment Management Inc. owned approximately 0.18% of Intrexon Corporation worth $5,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of XON. Swiss National Bank raised its position in shares of Intrexon Corporation by 2.2% during the first quarter. Swiss National Bank now owns 97,700 shares of the biotechnology company’s stock worth $1,936,000 after acquiring an additional 2,100 shares during the last quarter. UBS Asset Management Americas Inc. increased its holdings in Intrexon Corporation by 16.7% in the first quarter. UBS Asset Management Americas Inc. now owns 33,333 shares of the biotechnology company’s stock worth $661,000 after purchasing an additional 4,773 shares in the last quarter. Pacer Advisors Inc. increased its holdings in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 1,305 shares in the last quarter. Stifel Financial Corp increased its holdings in Intrexon Corporation by 15.5% in the first quarter. Stifel Financial Corp now owns 60,748 shares of the biotechnology company’s stock worth $1,209,000 after purchasing an additional 8,135 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Intrexon Corporation in the first quarter worth approximately $164,000. Institutional investors own 82.11% of the company’s stock.
In other news, CEO Randal J. Kirk purchased 132,625 shares of the company’s stock in a transaction dated Friday, August 11th. The shares were purchased at an average cost of $18.85 per share, for a total transaction of $2,499,981.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert B. Shapiro bought 2,850 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the completion of the transaction, the director now directly owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 144,569 shares of company stock worth $2,719,429. Company insiders own 55.10% of the company’s stock.
Intrexon Corporation (XON) opened at 17.99 on Friday. The stock’s market cap is $2.17 billion. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90. The company’s 50 day moving average price is $19.15 and its 200 day moving average price is $21.06.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to the consensus estimate of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period last year, the business posted ($0.42) EPS. Equities analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.
A number of equities research analysts have weighed in on XON shares. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Northland Securities set a $30.00 target price on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. JMP Securities reiterated an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a report on Thursday, October 5th. Finally, Griffin Securities reissued a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corporation in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $43.20.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).
Receive News & Stock Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related stocks with our FREE daily email newsletter.